Ryan Cohlhepp, serving as President and Chief Operating Officer at Bicara Therapeutics Inc. (NASDAQ: BCAX), has disclosed a series of stock transactions involving the disposal of company shares. The aggregate proceeds from these sales amounted to approximately $833,129. The transactions were executed on July 8 and July 9, 2026, and were conducted under the framework of a pre-arranged Rule 10b5-1 trading plan established on March 31, 2026.
The sequence of events began on July 8, when Mr. Cohlhepp acquired 18,750 shares of Bicara Therapeutics common stock. This acquisition was facilitated through the exercise of stock options, purchased at a price of $3.7898 per share, resulting in a total value of $71,058. The underlying options for these shares were structured to vest in sixteen equal quarterly installments following April 5, 2023, contingent upon Mr. Cohlhepp's continued service with the company.
Subsequent to the option exercise, Mr. Cohlhepp proceeded to sell a total of 28,750 shares of common stock across multiple transactions on July 8 and July 9. These sales generated the aforementioned total proceeds of approximately $833,129. The execution prices for these shares ranged between $28.7589 and $30.3549 per share. Both the acquisition via option exercise and the subsequent sales were executed pursuant to the established Rule 10b5-1 trading plan.
The timing of these transactions coincides with Bicara Therapeutics stock trading near its 52-week high of $30.99, with shares currently valued at $28.91. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value estimate. However, the company has delivered exceptional returns of 199% over the past year. The biotech firm maintains a market capitalization of $1.95 billion.
Following these transactions, Mr. Cohlhepp directly holds 181,641 shares of Bicara Therapeutics common stock. He also holds 70,502 derivative shares, consisting of stock options.
Concurrent with the executive activity, Bicara Therapeutics Inc. announced extended follow-up data from a Phase 1/1b study of ficerafusp alfa combined with pembrolizumab in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma. The data, presented at the 2026 American Society of Clinical Oncology Annual Meeting, revealed that at the 1500mg weekly dose, an estimated 31% of patients survived at three years.
Citizens reiterated a Market Outperform rating and maintained a $31.00 price target on Bicara Therapeutics, following the company's first-quarter 2026 financial results and updates on ongoing trials. Cantor Fitzgerald also reiterated an Overweight rating on the company after a meeting with senior management, highlighting the competitive landscape for head and neck cancer treatments. Citizens previously upgraded the stock price target based on Bicara's exploration of ficera in late-line MSS+ metastatic colorectal cancer. The company is targeting the late-line microsatellite stable KRAS/RAS/BRAF wild-type CRC population with a combination of ficera's TGF-β and EGFR inhibition with PD-(L)1 blockade. Analysts from Cantor Fitzgerald expressed confidence in the potential approval and adoption of three bispecific antibodies in Phase 3 development. These recent developments indicate ongoing progress in Bicara's clinical trials and strategic focus on cancer therapies.